Principles and current clinical landscape of multispecific antibodies against cancer
M Elshiaty, H Schindler, P Christopoulos - International journal of …, 2021 - mdpi.com
Building upon the resounding therapeutic success of monoclonal antibodies, and supported
by accelerating progress in engineering methods, the field of multispecific therapeutic …
by accelerating progress in engineering methods, the field of multispecific therapeutic …
Tebentafusp: T cell redirection for the treatment of metastatic uveal melanoma
BE Damato, J Dukes, H Goodall, RD Carvajal - Cancers, 2019 - mdpi.com
Metastatic disease from uveal melanoma occurs in almost 50% of patients suffering from this
ocular tumour, with median survival from development of symptoms being around 1 year. In …
ocular tumour, with median survival from development of symptoms being around 1 year. In …
Tebentafusp, a TCR/anti-CD3 bispecific fusion protein targeting gp100, potently activated antitumor immune responses in patients with metastatic melanoma
MR Middleton, C McAlpine, VK Woodcock… - Clinical Cancer …, 2020 - AACR
Purpose: Tebentafusp is a first-in-class bispecific fusion protein designed to target gp100 (a
melanoma-associated antigen) through a high affinity T-cell receptor (TCR) binding domain …
melanoma-associated antigen) through a high affinity T-cell receptor (TCR) binding domain …
Cellular differentiation of human monocytes is regulated by time-dependent interleukin-4 signaling and the transcriptional regulator NCOR2
Human in vitro generated monocyte-derived dendritic cells (moDCs) and macrophages are
used clinically, eg, to induce immunity against cancer. However, their physiological …
used clinically, eg, to induce immunity against cancer. However, their physiological …
miRIAD—integrating mi cro R NA i nter-a nd intragenic d ata
MicroRNAs (miRNAs) are a class of small (∼ 22 nucleotides) non-coding RNAs that post-
transcriptionally regulate gene expression by interacting with target mRNAs. A majority of …
transcriptionally regulate gene expression by interacting with target mRNAs. A majority of …
Progresses of T-cell-engaging bispecific antibodies in treatment of solid tumors
J Liu, J Zhu - International Immunopharmacology, 2024 - Elsevier
T-cell-engaging bispecific antibody (TCB) therapies have emerged as a promising
immunotherapeutic approach, effectively redirecting effector T cells to selectively eliminate …
immunotherapeutic approach, effectively redirecting effector T cells to selectively eliminate …
Surfaceome profiling suggests potential of anti-MUC1× EGFR bispecific antibody for breast cancer targeted therapy
Breast cancer (BC) treatment has traditionally been challenging due to tumor heterogeneity.
Bispecific antibodies (bsAbs) offer a promising approach for overcoming these challenges …
Bispecific antibodies (bsAbs) offer a promising approach for overcoming these challenges …
Structural principles of peptide-centric chimeric antigen receptor recognition guide therapeutic expansion
Peptide-centric chimeric antigen receptors (PC-CARs) recognize oncoprotein epitopes
displayed by cell-surface human leukocyte antigens (HLAs) and offer a promising strategy …
displayed by cell-surface human leukocyte antigens (HLAs) and offer a promising strategy …
T-Cell engagers in solid cancers—Current landscape and future directions
Simple Summary There are multiple strategies to target cancer cells, and among the rapidly
evolving field is the use of bispecific antibodies and T-cell engagers in the treatment of …
evolving field is the use of bispecific antibodies and T-cell engagers in the treatment of …
Molecular rules underpinning enhanced affinity binding of human T cell receptors engineered for immunotherapy
Immuno-oncology approaches that utilize T cell receptors (TCRs) are becoming highly
attractive because of their potential to target virtually all cellular proteins, including cancer …
attractive because of their potential to target virtually all cellular proteins, including cancer …